The manufacturer of leuprorelin (Prostap®) injections has written to healthcare professionals advising that the current presentation will be replaced with effect from the 4th of July 2011 and with a dual chamber syringe (DCS) system.
The one month (Prostap SR) and three month (Prostap 3) presentations are both affected by this change with the product license and price remaining unchanged. The manufacturer reports that the DCS system is simple to use and that the existing products will be discontinued in October 2011.
Action: Clinicians should be aware of this product presentation change. Clinicians who use Prostap products should ensure that usage instructions for the new product are followed.
|« Intensive dietary advice in early diabetes||Drug Safety Update - July 2011 »|